Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 15/20 | 0.45 |
| ▸ | CARM1 | Q86X55 | 8/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | XDH | P47989 | 1/20 | 0.36 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.36 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.36 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16204220 | 0.88 | PRMT1 (0.58) | PRMT1CARM1MEN1KMT2APRMT6 | |
| SCHEMBL16201419 | 0.88 | MEN1 (0.41) | MEN1KMT2AALDH1A1MAPTTP53 | |
| SCHEMBL19432083 | 0.87 | PRMT1 (0.46) | PRMT1CARM1 | |
| SCHEMBL17758376 | 0.87 | PRMT1 (0.43) | PRMT1CARM1MEN1KMT2AALDH1A1 | |
| SCHEMBL19432072 | 0.87 | PRMT1 (0.53) | PRMT1CARM1MEN1KMT2A | |
| SCHEMBL19432195 | 0.87 | PRMT1 (0.44) | PRMT1CARM1 | |
| SCHEMBL17758389 | 0.87 | PRMT1 (0.45) | PRMT1CARM1PRMT3PRMT6PRMT8 | |
| SCHEMBL19432320 | 0.87 | PRMT1 (0.45) | PRMT1CARM1PRMT3PRMT6PRMT8 | |
| SCHEMBL16194764 | 0.86 | PRMT1 (0.44) | PRMT1CARM1PRMT3PRMT6PRMT8 | |
| SCHEMBL16204201 | 0.86 | PRMT1 (0.42) | PRMT1CARM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9776972-B2 | Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof | EPIZYME INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-20160137609-A1 | PYRAZOLE DERIVATIVES AS ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137609-A1 | PYRAZOLE DERIVATIVES AS ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | PRMT1 1/4885CARM1 12/4885MEN1 1839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.